Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma

Misuzu Shimakage, Nobumasa Inoue, Kohichi Ohshima, Kunimitsu Kawahara, Takashi Oka, Kazuta Yasui, Kayoko Matsumoto, Hirokazu Inoue, Akihiro Watari, Shinji Higashiyama, Masuo Yutsudo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is an aggressive form of human leukemia/lymphoma. Although this disease is initiated by infection with human T-lymphotropic virus type 1 (HTLV-1), many HTLV-1 carriers survive for a long period without aggressive illness, suggesting that other factors may play roles in the progression of ATLL to an aggressive state. However, the mechanism involved in this progression still remains unclear. Previously, we have reported that ASY/Nogo mRNA was markedly down-regulated in human small-cell lung carcinomas, whereas it was expressed in normal tissues and other lung carcinomas, such as adenocarcinoma and squamous cell carcinoma. To understand whether or not ASY/Nogo gene is involved in the progression of ATLL, we examined the expression of ASY/Nogo mRNA in smoldering, chronic and aggressive ATLL, and found that the expression level of ASY/Nogo mRNA was markedly reduced in clinically aggressive ATLL. HTLV-1 Tax expression was not affected by the down-regulation of ASY/Nogo mRNA. These results indicate that the ASY/Nogo gene may act as a suppressor against ATLL progression, independent of Tax expression.

Original languageEnglish
Pages (from-to)1648-1653
Number of pages6
JournalInternational Journal of Cancer
Volume119
Issue number7
DOIs
Publication statusPublished - Oct 1 2006

Fingerprint

Adult T Cell Leukemia Lymphoma
Down-Regulation
Human T-lymphotropic virus 1
Messenger RNA
Small Cell Lung Carcinoma
Genes
Squamous Cell Carcinoma
Lymphoma
Leukemia
Adenocarcinoma
Carcinoma
Lung
Infection

Keywords

  • ASY/Nogo
  • ATLL
  • mRNA in situ hybridization
  • Progression
  • Tax

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma. / Shimakage, Misuzu; Inoue, Nobumasa; Ohshima, Kohichi; Kawahara, Kunimitsu; Oka, Takashi; Yasui, Kazuta; Matsumoto, Kayoko; Inoue, Hirokazu; Watari, Akihiro; Higashiyama, Shinji; Yutsudo, Masuo.

In: International Journal of Cancer, Vol. 119, No. 7, 01.10.2006, p. 1648-1653.

Research output: Contribution to journalArticle

Shimakage, M, Inoue, N, Ohshima, K, Kawahara, K, Oka, T, Yasui, K, Matsumoto, K, Inoue, H, Watari, A, Higashiyama, S & Yutsudo, M 2006, 'Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma', International Journal of Cancer, vol. 119, no. 7, pp. 1648-1653. https://doi.org/10.1002/ijc.22011
Shimakage, Misuzu ; Inoue, Nobumasa ; Ohshima, Kohichi ; Kawahara, Kunimitsu ; Oka, Takashi ; Yasui, Kazuta ; Matsumoto, Kayoko ; Inoue, Hirokazu ; Watari, Akihiro ; Higashiyama, Shinji ; Yutsudo, Masuo. / Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma. In: International Journal of Cancer. 2006 ; Vol. 119, No. 7. pp. 1648-1653.
@article{622da6406c4d42beb83bc401d8b11094,
title = "Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma",
abstract = "Adult T-cell leukemia/lymphoma (ATLL) is an aggressive form of human leukemia/lymphoma. Although this disease is initiated by infection with human T-lymphotropic virus type 1 (HTLV-1), many HTLV-1 carriers survive for a long period without aggressive illness, suggesting that other factors may play roles in the progression of ATLL to an aggressive state. However, the mechanism involved in this progression still remains unclear. Previously, we have reported that ASY/Nogo mRNA was markedly down-regulated in human small-cell lung carcinomas, whereas it was expressed in normal tissues and other lung carcinomas, such as adenocarcinoma and squamous cell carcinoma. To understand whether or not ASY/Nogo gene is involved in the progression of ATLL, we examined the expression of ASY/Nogo mRNA in smoldering, chronic and aggressive ATLL, and found that the expression level of ASY/Nogo mRNA was markedly reduced in clinically aggressive ATLL. HTLV-1 Tax expression was not affected by the down-regulation of ASY/Nogo mRNA. These results indicate that the ASY/Nogo gene may act as a suppressor against ATLL progression, independent of Tax expression.",
keywords = "ASY/Nogo, ATLL, mRNA in situ hybridization, Progression, Tax",
author = "Misuzu Shimakage and Nobumasa Inoue and Kohichi Ohshima and Kunimitsu Kawahara and Takashi Oka and Kazuta Yasui and Kayoko Matsumoto and Hirokazu Inoue and Akihiro Watari and Shinji Higashiyama and Masuo Yutsudo",
year = "2006",
month = "10",
day = "1",
doi = "10.1002/ijc.22011",
language = "English",
volume = "119",
pages = "1648--1653",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma

AU - Shimakage, Misuzu

AU - Inoue, Nobumasa

AU - Ohshima, Kohichi

AU - Kawahara, Kunimitsu

AU - Oka, Takashi

AU - Yasui, Kazuta

AU - Matsumoto, Kayoko

AU - Inoue, Hirokazu

AU - Watari, Akihiro

AU - Higashiyama, Shinji

AU - Yutsudo, Masuo

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Adult T-cell leukemia/lymphoma (ATLL) is an aggressive form of human leukemia/lymphoma. Although this disease is initiated by infection with human T-lymphotropic virus type 1 (HTLV-1), many HTLV-1 carriers survive for a long period without aggressive illness, suggesting that other factors may play roles in the progression of ATLL to an aggressive state. However, the mechanism involved in this progression still remains unclear. Previously, we have reported that ASY/Nogo mRNA was markedly down-regulated in human small-cell lung carcinomas, whereas it was expressed in normal tissues and other lung carcinomas, such as adenocarcinoma and squamous cell carcinoma. To understand whether or not ASY/Nogo gene is involved in the progression of ATLL, we examined the expression of ASY/Nogo mRNA in smoldering, chronic and aggressive ATLL, and found that the expression level of ASY/Nogo mRNA was markedly reduced in clinically aggressive ATLL. HTLV-1 Tax expression was not affected by the down-regulation of ASY/Nogo mRNA. These results indicate that the ASY/Nogo gene may act as a suppressor against ATLL progression, independent of Tax expression.

AB - Adult T-cell leukemia/lymphoma (ATLL) is an aggressive form of human leukemia/lymphoma. Although this disease is initiated by infection with human T-lymphotropic virus type 1 (HTLV-1), many HTLV-1 carriers survive for a long period without aggressive illness, suggesting that other factors may play roles in the progression of ATLL to an aggressive state. However, the mechanism involved in this progression still remains unclear. Previously, we have reported that ASY/Nogo mRNA was markedly down-regulated in human small-cell lung carcinomas, whereas it was expressed in normal tissues and other lung carcinomas, such as adenocarcinoma and squamous cell carcinoma. To understand whether or not ASY/Nogo gene is involved in the progression of ATLL, we examined the expression of ASY/Nogo mRNA in smoldering, chronic and aggressive ATLL, and found that the expression level of ASY/Nogo mRNA was markedly reduced in clinically aggressive ATLL. HTLV-1 Tax expression was not affected by the down-regulation of ASY/Nogo mRNA. These results indicate that the ASY/Nogo gene may act as a suppressor against ATLL progression, independent of Tax expression.

KW - ASY/Nogo

KW - ATLL

KW - mRNA in situ hybridization

KW - Progression

KW - Tax

UR - http://www.scopus.com/inward/record.url?scp=33747470604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747470604&partnerID=8YFLogxK

U2 - 10.1002/ijc.22011

DO - 10.1002/ijc.22011

M3 - Article

VL - 119

SP - 1648

EP - 1653

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -